NextCell publishes its Year-End Report 2023/2024

October 24, 2024

NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Year-End Report for the period September 1, 2023 – August 31, 2024. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.

 

Fourth quarter (2024-06-01 until 2024-08-31)

  • Operating income amounted to 1,696 (3,947) TSEK, of which Cellaviva amounted to 1,643 (2,758) TSEK.
  • Net Income amounted to 1,643 (2,758) SEK
  • Operating result amounted to -13,249 (-8,640) TSEK.
  • Earnings per share* amounted to -0.22 (-0.25) SEK.
  • Cash and Bank amounted to 46,791 (50,025) TSEK.
  • Solidity** amounted to 83.8 (85.3) percent.
     

Twelve months (2023-09-01 till 2024-08-31)

  • Operating income amounted to 11,278 (13,955) TSEK, of which Cellaviva amounted to 10,665 (10,113) TSEK.
  • Net Income amounted to 10,665 (10,113) SEK
  • Operating result amounted to -41,960 (-39,812) TSEK.
  • Earnings per share* amounted to -1.03 (-1.16) SEK.
  • The Board of Directors proposes that no dividend shall be paid for the financial year.
     

Earnings per share: Profit for the period divided by average number of shares. Average number of shares for the fourth quarter 2023/2024: 59,979,085 (34,379,523) shares. Number of shares in NextCell as of August 31, 2024: 73,091,327 (34,379,523) shares.

**Solidity: Equity to total balance sheet.

Significant events in the fourth quarter

  • At the beginning of June, NextCell announced that the Company had agreed on a so-called top guarantee of a total of approximately SEK 8.0 million, corresponding to approximately 20.0 percent of the issue volume. Through the additional top guarantee, the Rights Issue is covered up to approximately 100 percent by subscription and guarantee commitments.
     
  • At the beginning of June, NextCell announced that the company's Board of Directors, management and key employees, who have previously entered into subscription commitments of up to a total of approximately SEK 1.5 million, announced that they will register their interest in subscribing for units for a total of approximately SEK 3.3 million, corresponding to 8.2 percent of the rights issue.
  • The company announced in mid-June that the Data Safety Monitoring Board for the ProTrans-Young study had recommended the principal investigator, Professor Per-Ola Carlsson, to continue with treatment of children in the younger age group 7-11 years. This decision is based on a review of all safety data from the 36 children and adolescents who have participated in the study so far. The recruitment of the 30 children aged 7-11 will begin in August 2024.
  • In mid-June, NextCell announced the outcome of the rights issue. The rights issue was oversubscribed and NextCell will receive approximately SEK 40.1 million before deduction of issue costs.
  • At the beginning of July, NextCell announced that it is carrying out a directed share issue to guarantors in connection with the completed rights issue, corresponding to 894,232 units, which reduces the guarantee compensation by approximately SEK 1.34 million.
     

Significant after the fourth quarter

  • At the beginning of September, the company presented new long-term clinical data at the International Society for Cell and Gene Therapy (ISCT) 2024 Regional Meeting. The results show the long-term safety of the treatment, efficacy by preserving endogenous insulin production and more health benefits in patients of patients with type 1 diabetes (T1D) such as lower BMI and blood pressure.
     
  • At the end of September, the company announced that the first four children in the age group 7–11 years had been treated in the latest part of the ProTrans-Young study, and that four more children had been screened and are expected to start their treatment shortly. These advances mark an important milestone in the course of the study that is progressing faster than expected.
     
  • The company announced in early October that ProTrans was highlighted as a promising treatment for type 1 diabetes in Dagens Medicin.
     

This disclosure contains information that NextCell Pharma AB is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 24-10-2024 07:30 CET.

For more information about NextCell Pharma, please contact
Mathias Svahn, CEO
Patrik Fagerholm, CFO
Tel: +46 8 735 55 95
E-mail: info@nextcellpharma.com
Website:www.nextcellpharma.com

Linkedin: https://www.linkedin.com/NextCell-Pharma
Twitter: https://twitter.com/NextCellPharma


For more information about Cellaviva, please contact
Sofie Falk Jansson, CEO Cellaviva AB
Tel: +46 8 735 20 10
E-mail: info@cellaviva.se
Website:www.cellaviva.se


Facebook: https://www.facebook.com/cellavivasverige
Instagram: https://www,instagram.com/cellaviva

Download attachmentRead full press release on Cision (external link)
2024-03-14
NextCell establishes QVance to meet the Nordic’s need for quality analytics
NextCell Pharma AB ("NextCell" or the "Company") today announces that it has formed a subsidiary company specialising in quality control analytics. QVance’s launch is a strategic addition for NextCell as the company grows its presence in the advanced therapy market. QVance will specialise in quality analyses for advanced therapeutic companies, including NextCell, in the growing cell and gene therapy market. QVance will address a large gap in the Nordic region, where there is a significant lack of local providers in this area.
Read moreRead more
2024-02-27
NextCell Pharma’s updated growth strategy
NextCell Pharma AB ("NextCell" or the "Company") today announces that the Company has decided to implement strategic changes. The new strategic direction means, amongst other things, that Cellaviva will become a wholly owned subsidiary and that the company's GMP facility will have new sources of revenue. The strategic changes will also result in cost savings as a result of staff reduction.
Read moreRead more
2024-02-14
NextCell Pharma presents at Redeye Theme: Regenerative Medicine/Cell Therapy
Today Wednesday on February 14th at 10.30 CET Dr. Mathias Svahn, CEO of NextCell Pharma AB (“NextCell" or the"Company"), will present the latest developments in the company at Redeye.
Read moreRead more
2024-01-25
NextCell publishes its Interim Report 1 2023/2024
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Interim Report 1 for the period September 1, 2023 – November 30, 2023. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.  
Read moreRead more
2024-01-24
Updates regarding NextCell’s Clinical Trials with ProTrans
NextCell Pharma has several ongoing clinical trials with ProTrans. The largest ongoing study ProTrans Young, which includes 66 patients, is progressing well. All 30 patients in the older age group have been recruited and will be treated with ProTrans. In the long-term follow-up studies ProTrans-Obs and ProTrans-Repeat the first diabetes patients have now completed the studies after five years of follow-up.
Read moreRead more
2023-12-13
NextCell Pharma has compiled a Q&A section
NextCell Pharma AB ("NextCell" or the "Company") has compiled questions from the company’s stakeholders in a Q&A section. The questions and answers can be accessed via the link below.
Read moreRead more
2023-11-06
Repeated treatment with ProTrans is immunologically safe
NextCell Pharma AB ("NextCell" or the "Company") today announces that multiple treatments with ProTrans cell therapy does not induce donor specific antibodies in type-1 diabetes patients. A detailed analysis of how the immune system reacts to infusion of ProTrans cells show that treatment can be given to any adult type 1 diabetic, irrespective of pre-existing HLA antibodies.
Read moreRead more
2023-10-26
NextCell publishes its Year-End Report 2022/2023
NextCell Pharma AB (publ) (NXTCL or NextCell) publishes its Year-End Report for the period September 1, 2022 – August 31, 2023. The report is available on the company’s website: https://www.nextcellpharma.com/en/investors#financial-report. NextCells share is traded on Nasdaq First North Growth Market under the ticker "NXTCL". The amount in brackets refers to the corresponding period in the previous year.  
Read moreRead more